<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168025</url>
  </required_header>
  <id_info>
    <org_study_id>ZLB03_002CR</org_study_id>
    <nct_id>NCT00168025</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)</brief_title>
  <official_title>A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the effect of IgPro10 on the prevention of
      serious bacterial infections in patients with primary immunodeficiency.

      As secondary endpoints the rate of overall infections, the tolerability and safety of IgPro10
      are studied.

      A part of the patients are participating in a pharmacokinetic substudy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of acute serious bacterial infections</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days out of work / school due to underlying PID</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events temporally associated with study drug infusion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough levels of total IgG serum concentrations</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Agammaglobulinemia</condition>
  <condition>IgG Deficiency</condition>
  <condition>Common Variable Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>IgPro10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulins Intravenous (Human)</intervention_name>
    <arm_group_label>IgPro10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with primary immunodeficiency

          -  Patients who have received stable IVIG therapy at 3- or 4-weekly intervals for at
             least 6 months

        Key Exclusion Criteria:

          -  Newly diagnosed PID

          -  Allergic reactions to immunoglobulins or other blood products

          -  Administration of steroids (daily â‰¥ 0.15 mg prednisone equivalent/kg/day) or other
             immunosuppressive drugs

          -  Concomitant diseases such as hypoalbuminemia, protein-losing enteropathies, kidney
             diseases with proteinuria, malignancies of lymphoid cells (e.g. lymphocytic leukemia),
             and recent history of migraine

          -  History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart
             failure, severe hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT00168025&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <reference>
    <citation>Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol. 2010 May;30(3):442-8. doi: 10.1007/s10875-010-9373-x. Epub 2010 Mar 10.</citation>
    <PMID>20217199</PMID>
  </reference>
  <results_reference>
    <citation>Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J; IgPro10 in PID study group. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009 Jan;29(1):137-44. doi: 10.1007/s10875-008-9231-2. Epub 2008 Sep 24.</citation>
    <PMID>18814020</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunoglobulin Intravenous</keyword>
  <keyword>Agammaglobulinemia</keyword>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Common variable immunodeficiency</keyword>
  <keyword>Immunoglobulin G</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>IgG Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

